Log in

NASDAQ:REXNRexahn Pharmaceuticals Stock Price, Forecast & News

+0.06 (+2.45 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $2.51
50-Day Range
MA: $2.09
52-Week Range
Now: $2.51
Volume13,553 shs
Average Volume32,649 shs
Market Capitalization$10.09 million
P/E RatioN/A
Dividend YieldN/A
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:REXN



Sales & Book Value

Annual SalesN/A
Book Value$2.35 per share


Net Income$-8,640,000.00


Market Cap$10.09 million
Next Earnings Date8/5/2020 (Estimated)

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter.

Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

How has Rexahn Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rexahn Pharmaceuticals' stock was trading at $1.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REXN shares have increased by 31.4% and is now trading at $2.5099. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rexahn Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Rexahn Pharmaceuticals.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Rexahn Pharmaceuticals.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.15) earnings per share for the quarter. The company earned $1.15 million during the quarter. View Rexahn Pharmaceuticals' earnings history.

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Shares of Rexahn Pharmaceuticals reverse split on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

Media stories about REXN stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutRexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a decrease in short interest in April. As of April 30th, there was short interest totaling 75,200 shares, a decrease of 14.5% from the April 15th total of 88,000 shares. Based on an average daily trading volume, of 400,600 shares, the short-interest ratio is currently 0.2 days. Currently, 1.9% of the shares of the company are short sold. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SLS International (SLS), Novavax (NVAX), Dynavax Technologies (DVAX), AcelRx Pharmaceuticals (ACRX), CytRx (CYTR), Biopharmx (BPMX) and Madrigal Pharmaceuticals (MDGL).

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the following people:
  • Douglas J. Swirsky, President, CEO, CFO, Secretary & Director
  • D J Kim, Vice President, Head-Research & Development
  • Lisa M. Nolan, Chief Business Officer

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

How do I buy shares of Rexahn Pharmaceuticals?

Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of REXN stock can currently be purchased for approximately $2.51.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $10.09 million. Rexahn Pharmaceuticals employs 10 workers across the globe.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is www.rexahn.com.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.